SK Biopharmaceuticals rose 160 percent from its offer price on its first day of trade, hitting two stock exchange-imposed limits on the way up. By market capitalization, it is now Korea's 27th largest company, just ahead of
Past performance, as they say, is no guarantee of future results, but Korean investors are not moved by that warning. With a flurry of successful initial public offerings (IPOs) and some big names on the horizon, the ants are piling in.
SK Biopharmaceuticals, a wholly owned subsidiary of SK Holdings, has set an all-time record for deposits and the subscription rate in its initial public offering (IPO),
SK Biopharmaceuticals is hoping for a near 1-trillion-won ($823 million) initial public offering (IPO) bonanza that will be the company's silver bullet, allowing it to secure a beachhead in the cutthroat global pharmaceutical industry.
Kakao Games is preparing for an initial public offering (IPO). The game company majority owned by Kakao said Thursday afternoon that it submitted documents for a preliminary examination to be listed on the Kosdaq market.
The Korea Exchange (KRX) recorded a grand total of zero initial public offerings (IPOs) in April, as the coronavirus outbreak slowed the economy and scared off investors as stock prices crashed in March.
SK Biopharmaceuticals, a wholly-owned subsidiary of SK Holdings, on Tuesday filed for a planned public listing set for June that could raise nearly 1 trillion won ($816 million).